Перспективы применения клеточной терапии в ветеринарии

Концепция клеточной терапии основана на введении в организм эукариориотических клеток с целью лечения патологических состояний. Изначально возникшая в области медицины человека, клеточная терапия в ветеринарии находит все большее применение и активно развивается. В данном исследовании проанализированы и обобщены данные о применении клеточной терапии в ветеринарии, проведен обзор клинических исследований и нормативных документов. Целью нашего исследования было оценить перспективы применения терапии стволовыми клетками в ветеринарии, и основные направления клинических исследований, оценить их эффективность и определить основные критические моменты в практической реализации. Нами было установлено, что наибольшее количество исследований посвящено эффективности мезенхимных стволовых клеток в лечении остеоартроза у лошадей, спинальных травм у собак и кошек, острых и хронических повреждений кожи у собак. Основными направлениями применения клеточной терапии в ветеринарии является лечение хронических заболеваний суставов, острых и хронических повреждений спинного мозга и кожи. В обзоре представлены наиболее значимые достижения в области клеточной терапии мезенхимными стволовыми клетками в ветеринарии, а также обсуждаются проблемы контроля качества и правового регулирования в этой области. Несмотря на значительный прогресс в последнее время, ветеринарная регенеративная медицина находится только на начальном этапе развития, хотя есть все предпосылки для скорого внедрения ее в рутинную клиническую практику. Клеточная терапия позволит эффективно восполнять дефекты различных тканей, избежать высокоинвазивных вмешательств и значительно сократить сроки выздоровления. Создание аналогичных доступных препаратов является перспективной задачей для ветеринарии в России, а реализация подхода «Единое здоровье» будет способствовать эффективному развитию отрасли.

1. 29 September 2004 Symposium.https://www.oneworldonehealth.org/sept2004/owoh_sept04.html. Access date: August 31, 2025

2. Arzi B, Webb TL, Koch TG, et al. Cell Therapy in Veterinary Medicine as a Proof-of-Concept for Human Therapies: Perspectives From the North American Veterinary Regenerative Medicine Association. Front Vet Sci. 2021;8:779109. Published 2021 Nov 30. doi:10.3389/fvets.2021.779109

3. Gage F.H. Cell therapy // Nature. 1998. V. 392. P. 18–24

4. Rodriguez-Fuentes DE, Fernandez-Garza LE, Samia-Meza JA, Barrera-Barrera SA, Caplan AI, Barrera-Saldana HA. Mesenchymal stem cells current clinical applications: a systematic review. Arch Med Res. (2020) 52:93–101. doi: 10.1016/j.arcmed.2020.08.006

5. Bogers S. H. (2018). Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know. Frontiers in veterinary science, 5, 70. https://doi.org/10.3389/fvets.2018.00070

6. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, et al. Human bone marrow-derived mesenchymal stem cells do not undergo trans-formation after long-term in vitro culture and do not exhibit telomere mainte-nance mechanisms. Cancer Res (2007) 67(19):9142–9. doi: 10.1158/0008-5472.CAN-06-4690

7. Kasashima Y, Ueno T, Tomita A, Goodship AE, Smith RK. Optimization of bone marrow aspiration from the equine sternum for the safe recovery of mes-enchymal stem cells. Equine Vet J (2011) 43(3):288–94. doi: 10.1111/j.2042-3306.2010.00215.x

8. Lombana KG, Goodrich LR, Phillips JN, Kisiday JD, Ruple-Czerniak A, McIlwraith CW. An investigation of equine mesenchymal stem cell characteris-tics from different harvest sites: more similar than not. Front Vet Sci (2015) 2:67. doi: 10.3389/fvets.2015.00067

9. Delling U, Lindner K, Ribitsch I, Jülke H, Brehm W. Comparison of bone mar-row aspiration at the sternum and the tuber coxae in middle-aged horses. Can J Vet Res (2012) 76(1):52–6

10. Humenik, F., Maloveská, M., Hudáková, N., Petroušková, P., Šufliarska, Z., Horňáková, Ľ., Valenčáková, A., Kožár, M., Šišková, B., Mudroňová, D., Bartkovský, M., & Čížková, D. (2023). Impact of Canine Amniotic Mesenchymal Stem Cell Conditioned Media on the Wound Healing Process: In Vitro and In Vivo Study. International journal of molecular sciences, 24(9), 8214. https://doi.org/10.3390/ijms24098214

11. Picazo, R.A.; Rojo, C.; RodriguezQuiros, J.; González-Gil, A. Current Advances in Mesenchymal Stem Cell Therapies Applied to Wounds and Skin, Eye, and Neuromuscular Diseases in Companion Animals. Animals 2024, 14, 1363. https://doi.org/10.3390/ani14091363

12. Magellan. Registration to Order Stem Cells Online (2014). Available from: https://www.veterinarystemcells.com.au/loginform/ (Accessed: September 1, 2025

13. Hill JA, Cassano JM, Goodale MB, Fortier LA. Antigenicity of mesen-chymal stem cells in an inflamed joint environment. Am J Vet Res (2017) 78(7):867–75. doi: 10.2460/ajvr.78.7.867

14. Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R III, et al. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model. Stem Cell Res Ther (2017) 8(1):42. doi: 10.1186/s13287-017-0503-8

15. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science (1999) 284(5411):143–7. doi: 10.1126/science.284.5411.143

16. Taylor SE, Clegg PD. Collection and propagation methods for mesenchymal stromal cells. Vet Clin N Am (2011) 27(2):263–74. doi: 10.1016/j.cveq.2011.05.003

17. Chu CR, Fortier LA, Williams A, Payne KA, McCarrel TM, Bowers ME, et al. Minimally manipulated bone marrow concentrate compared with micro-fracture treatment of full-thickness chondral defects: a one-year study in an eq-uine model. J Bone Joint Surg Am (2018) 100(2):138–46. doi: 10.2106/JBJS.17.00132

18. Arnhold SJ, Goletz I, Klein H, Stumpf G, Beluche LA, Rohde C, et al. Isolation and characterization of bone marrow-derived equine mesenchymal stem cells. Am J Vet Res (2007) 68(10):1095–105. doi: 10.2460/ajvr.68.10.1095

19. Black LL, Gaynor J, Gahring D, Adams C, Aron D, Harman S, et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther (2007) 8(4):272–84

20. Ranera B, Ordovas L, Lyahyai J, Bernal ML, Fernandes F, Remacha AR, et al. Comparative study of equine bone marrow and adipose tissue-derived mesenchymal stromal cells. Equine Vet J (2012) 44(1):33–42. doi: 10.1111/j.2042-3306.2010.00353.x

21. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adi-pose tissue. Stem Cells (2006) 24(5):1294–301. doi: 10.1634/stemcells.2005-0342

22. Clark KC, Kol A, Shahbenderian S, Granick JL, Walker NJ, Borjesson DL. Canine and equine mesenchymal stem cells grown in serum free media have altered immunophenotype. Stem Cell Rev (2016) 12 (2):245–56. doi: 10.1007/s12015-015-9638-0

23. Russell KA, Gibson TW, Chong A, Co C, Koch TG. Canine platelet ly-sate is inferior to fetal bovine serum for the isolation and propagation of canine adipose tissue- and bone marrow-derived mesenchymal stromal cells. PLoS One (2015) 10(9):e0136621. doi: 10.1371/journal.pone.0136621

24. Garvican ER, Cree S, Bull L, Smith RK, Dudhia J. Viability of equine mesenchymal stem cells during transport and implantation. Stem Cell Res Ther (2014) 5(4):94. doi: 10.1186/scrt483

25. Mercati F, Pascucci L, Curina G, Scocco P, Tardella FM, Dall'Aglio C, et al. Evaluation of storage conditions on equine adipose tissue-derived multipotent mesenchymal stromal cells. Vet J (2014) 200(2):339–42. doi: 10.1016/j.tvjl.2014.02.018

26. Bronzini I, Patruno M, Iacopetti I, Martinello T. Influence of temperature, time and different media on mesenchymal stromal cells shipped for clinical application. Vet J (2012) 194(1):121–3. doi: 10.1016/j.tvjl.2012.03.010

27. Lang HM, Schnabel LV, Cassano JM, Fortier LA. Effect of needle diameter on the viability of equine bone marrow derived mesenchymal stem cells. Vet Surg (2017) 46 (5):731–7. doi: 10.1111/vsu.12639

28. Bohannon LK, Owens SD, Walker NJ, Carrade DD, Galuppo LD, Borjesson DL. The effects of therapeutic concentrations of gentamicin, amikacin and hyaluronic acid on cultured bone marrow-derived equine mesenchymal stem cells. Equine Vet J (2013) 45 (6):732–6. doi: 10.1111/evj.12045

29. Dahr M, Amelse L, Neilsen N, Favi P, Carter-Arnold J. Platelet-rich plasma enhances the cellular function of equine bone marrow-derived mesenchymal stem cells. J Stem Cell Res Ther (2015) 5(4):278. doi: 10.4172/2157-7633.1000278

30. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheumatism (2003) 48:3464–74. doi: 10.1002/art.11365

31. Barker WH, Smith MR, Minshall GJ, Wright IM. Soft tissue injuries of the tarsocrural joint: a retrospective analysis of 30 cases evaluated arthroscopially. Equine Vet J (2013) 45(4):435–41. doi: 10.1111/j.2042-3306.2012.00685.x

32. Canapp SO Jr, Leasure CS, Cox C, Ibrahim V, Carr BJ. Partial cranial cruciate ligament tears treated with stem cell and platelet -rich plasma combina-tion therapy in 36 dogs: a retrospective study. Front Vet Sci (2016) 3:112. doi: 10.3389/fvets.2016.00112

33. Ireland JL, Clegg PD, McGowan CM, McKane SA, Chandler KJ, Pinch-beck GL. Disease prevalence in geriatric horses in the United Kingdom: veterinary clinical assessment of 200 cases. Equine Vet J (2012) 44 (1):101–6. doi: 10.1111/j.2042-3306.2010.00361.x

34. Ferris DJ, Frisbie DD, McIlwraith CW, Kawcak CE. Current joint thera-py usage in equine practice: a survey of veterinarians 2009. Equine Vet J (2011) 43(5):530–5. doi: 10.1111/j.2042-3306.2010.00324.x

35. Kim, Y.; Lee, S. H.; Kim, W. H.; Kweon, O.K. Transplantation of adipose derived mesenchymal stem cells for acute thoracolumbar disc disease with no deep pain perception in dogs. J. Vet. Sci. 2016, 17, 123–126.

36. Bach, F.S.; Rebelatto, C.L.K.; Fracaro, L.; Senegalia, A.C.; Fragoso, F.Y.I.; Daga, D.R.; Brofman, P.R.S.; Pimpão, C. T.; Engracia Filho, J.R.; Monti-ani-Ferreira, F.; et al. Comparison of the efficacy of surgical decompression alone and combined with canine adipose tissue-derived stem cell transplantation in dogs with acute thoracolumbar disk disease and spinal cord injury. Front. Vet. Sci. 2019, 6, 383.

37. Escalhao, C.C.M.; Ramos, I.P.; Hochman -Mendez, C.; Brunswick, T.H.K.; Souza, S.A.L.; Gutfilen, B.; Dos Santos Goldenberg, R.C.; Coelho-Sampaio, T. Safety of allogeneic canine adipose tissue-derived mesenchymal stem cell intraspinal transplantation in dogs with chronic spinal cord injury. Stem Cells Int. 2017, 2017, 3053759.

38. Penha, E.M.; Aguiar, P. H.; BarrouinMelo, S. M.; de Lima, R. S.; da Silveira, A.C.; Otelo, A.R.; Pinheiro, C. M.; RibeiroDos-Santos, R.; Soares, M.B. Clinical neurofunctional rehabilitation of a cat with spinal cord injury after hemilaminectomy and autologous stem cell transplantation. Int. J Stem Cells 2012, 5, 146–150.

39. Kim, E.Y.; Kil, T.Y.; Kim, M.K. Case report: Amniotic fluid-derived mesenchymal stem cell treatment in a dog with a spinal cord injury. Vet. Anim. Sci. 2023, 22, 100318

40. Besalti, O.; Aktas, Z.; Can, P.; Akpinar, E.; Elcin, A. E.; Elcin, Y.M. The use of autologous neurogenically-induced bone marrow-derived mesenchymal stem cells for the treatment of paraplegic dogs without nociception due to spinal trauma. J. Vet. Med. Sci. 2016, 78, 1465–1473.

41. Branco, E.; Alves, J. G. R.; Pinheiro, L.L.; Coutinho, L.N.; Gomes, C.R.M.; Galvão, G. R.; de Oliveira Dos Santos, G.R.; Moreira, L.F.M.; David, M.B.M.; Martins, D.M.; et al. Can paraplegia by disruption of the spinal cord tissue be reversed? The signs of a new perspective. Anat. Rec. 2020, 303, 1812–1820.

42. Orlandin, J.R.; Gomes, I.D.S.; Sallum Leandro, S. F.; Fuertes Cagnim, A.; Casals, J.B.; Carregaro, A.B.; Freitas, S. H.; Machado, L.C.; Reis Castiglioni, M.C.; Garcia Alves, A. L.; et al. Treatment of chronic spinal cord injury in dogs using amniotic membrane-derived stem cells: Preliminary results. Stem Cells Cloning 2021, 14, 39–49.

43. Sharun, K.; Rawat, T.; Kumar, R.; Chandra, V.; Saxena, A.C.; Pawde, A.M.; Kinjavdekar, P.; Amarpal; Sharma, G.T. Clinical evaluation following the percutaneous transplantation of allogenic bone marrow-derived mesenchymal stem cells (aBM-MSC) in dogs affected by vertebral compression fracture. Vet. Anim. Sci. 2020, 10, 100152.

44. Sharun, K.; Kumar, R.; Chandra, V.; Saxena, A.C.; Pawde, A.M.; Kinjavdekar, P.; Dhama, K.; Amarpal; Sharma, G.T. Percutaneous transplantation of allogenic bone marrow-derived mesenchymal stem cells for the management of paraplegia secondary to Hansen type I intervertebral disc herniation in a Beagle dog. Iran. J. Vet. Res. 2021, 22, 161–166.

45. Vikartovska, Z.; Kuricova, M.; Farbakova, J.; Liptak, T.; Mudronova, D.; Humenik, F.; Madari, A.; Maloveska, M.; Sykova, E.; Cizkova, D. Stem cell conditioned medium treatment for canine spinal cord injury: Pilot feasibility study. Int. J. Mol. Sci. 2020, 21, 5129.

46. Bhat, I.A.; Sivanarayanan, T.B.; Somal, A.; Pandey, S.; Bharti, M.K.; Panda, B.S.K.; Indu, B.; Verma, M. J. A.; Sonwane, A.; Kumar, G.S.; et al. An allogenic therapeutic strategy for canine spinal cord injury using mesenchymal stem cells. J Cell. Physiol. 2019, 234, 2705–2718.

47. Chen, C.C.; Yang, S. F.; Wang, I. K.; Hsieh, S. Y.; Yu, J. X.; Wu, T. L.; Hu-ong, W. J.; Su, M.H.; Yang, H. L.; Chang, P. C.; et al. The long-term efficacy study of multiple allogeneic canine adipose tissue-derived mesenchymal stem cells transplantations combined with surgery in four dogs with lumbosacral spinal cord injury. Cell Transplant. 2022, 31, 9636897221081487.

48. Kim, B.G.; Kang, Y. M.; Phi, J. H.; Kim, Y.H.; Hwang, D.H.; Choi, J.Y.; Ryu, S.; Elastal, A.E.; Paek, S. H.; Wang, K.C.; et al. Implantation of polymer scaffolds seeded with neural stem cells in a canine spinal cord injury model. Cytotherapy 2010, 12, 841–845.

49. Ryu, H.H.; Kang, B. J.; Park, S. S.; Kim, Y.; Sung, G. J.; Woo, H.M.; Kim, W. H.; Kweon, O.K. Comparison of mesenchymal stem cells derived from fat, bone marrow, Wharton’s jelly, and umbilical cord blood for treating spinal cord injuries in dogs. J. Vet. Med. Sci. 2012, 74, 1617–1630.

50. Han, S.; Xiao, Z.; Li, X.; Zhao, H.; Wang, B.; Qiu, Z.; Li, Z.; Mei, X.; Xu, B.; Fan, C.; et al. Human placenta-derived mesenchymal stem cells loaded on linear ordered collagen scaffold improves functional recovery after complexly transected spinal cord injury in canine. Sci. China Life Sci. 2018, 61, 2–13.

51. Deng, W.S.; Yang, K.; Liang, B.; Liu, Y. F.; Chen, X.Y.; Zhang, S. Colla-gen/heparin sulfate scaffold combined with mesenchymal stem cells treatment for canines with spinal cord injury: A pilot feasibility study. J. Orthop. Surg. 2021, 29, 23094990211012293

52. Abdallah, A.N., Shamaa, A.A., ElTookhy, O.S. et al. Comparison be-tween stem cell therapy and stem cell derived exosomes on induced multiple sclerosis in dogs. BMC Vet Res 20, 90 (2024). https://doi.org/10.1186/s12917-024-03920-4

53. Enciso, N.; Avedillo, L.; Fermin, M. L.; Fragio, C.; Tejero, C. Cutaneous wound healing: Canine allogeneic ASC therapy. Stem Cell Res. Ther. 2020, 11, 261

54. Enciso, N.; Avedillo, L.; Fermin, M. L.; Fragio, C.; Tejero, C. Regenerative potential of allogeneic adipose tissue-derived mesenchymal cells in canine cutaneous wounds. Acta Vet. Scand. 2020, 62, 13.

55. Ribeiro, J.; Pereira, T.; Amorim, I.; Caseiro, A.R.; Lopes, M.A.; Lima, J.; Gartner, A.; Santos, J.D.; Bártolo, P. J.; Rodrigues, J.M.; et al. Cell therapy with human MSCs isolated from the umbilical cord Wharton jelly associated to a PVA membrane in the treatment of chronic skin wounds. Int. J. Med. Sci. 2014, 11, 979–987.

56. Zakirova, E.Y.; Shalimov, D.V.; Garanina, E.E.; Zhuravleva, M.N.; Rutland, C.S.; Rizvanov, A.A. Use of biologically active 3D matrix for extensive skin defect treatment in veterinary practice: Case report. Front. Vet. Sci. 2019, 6, 76.

57. Villatoro, A.J.; Hermida-Prieto, M.; Fernández, V.; Fariñas, F.; Alcoholado, C.; Rodríguez-García, M.I.; Mariñas-Pardo, L.; Becerra, J. Allogeneic adipose-derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: Clinical efficacy and safety. Vet. Rec. 2018, 183, 654

58. Kaur, G.; Ramirez, A.; Xie, C.; Clark, D.; Dong, C.; Maki, C.; Ramos, T.; Izadyar, F.; Najera, S.O.L.; Harb, J.; et al. A doubleblinded placebo-controlled evaluation of adipose-derived mesenchymal stem cells in the treatment of canine atopic dermatitis. Vet. Res. Commun. 2022, 46, 251–260

59. de Oliveira Ramos, F.; Malard, P. F.; Brunel, H.D.S.S.; Paludo, G. R.; de Castro, M.B.; da Silva, P.H.S.; da Cunha BarretoVianna, A.R. Canine atopic dermatitis attenuated by mesenchymal stem cells. J Adv. Vet. Anim. Res. 2020, 7, 554–565.

60. Enciso, N.; Amiel, J.; Pando, J.; Enciso, J. Multidose intramuscular al-logeneic adipose stem cells decrease the severity of canine atopic dermatitis: A pilot study. Vet. World 2019, 12, 1747–1754.

61. Chen, S.Y.; Yang, R. L.; Wu, X.C.; Zhao, D.Z.; Fu, S.P.; Lin, F.Q.; Li, L.Y.; Yu, L.M.; Zhang, Q.; Zhang, T. Mesenchymal stem cell transplantation: Neuroprotection and nerve regeneration after spinal cord injury. J. Inflamm. Res. 2023, 16, 4763–4776

62. Dall'Olio, A.J.; Matias, G.S.S.; Carreira, A.C.O.; de Carvalho, H. J. C.; van den Broek Campanelli, T.; da Silva, T.S.; da Silva, M.D.; Abreu-Silva, A. L.; Miglino, M.A. Biological graft as an innovative biomaterial for complex skin wound treatment in dogs: A preliminary report. Materials 2022, 15, 6027

63. FDA. Cell and Tissue Products for Animals (2025). Available from: https://www.fda.gov/animal-veterinary/biotechnology-products-cvm-animals-andanimal-food/cell-and-tissue-productsanimals (Accessed September 1, 2025)

64. FDA. Guidance for Industry: Cell-Based Products for Animal Use. Rockville, MD: United States Food and Drug Administration Center for Veterinary Medicine (2015). Available from: https://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM405679.pdf (Accessed September 1, 2025).